Denali Therapeutics (DNLI) Issues Quarterly Earnings Results

Denali Therapeutics (NASDAQ:DNLI) posted its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.13), Fidelity Earnings reports. The business had revenue of $1.20 million for the quarter, compared to analysts’ expectations of $3.00 million.

Shares of DNLI stock traded down $0.67 during trading hours on Friday, hitting $16.68. 207,840 shares of the company were exchanged, compared to its average volume of 368,850. Denali Therapeutics has a 52-week low of $12.32 and a 52-week high of $25.79. The firm has a market cap of $1.65 billion and a P/E ratio of -2.83.

In other news, insider Ryan J. Watts sold 18,333 shares of the firm’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $19.06, for a total transaction of $349,426.98. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Carole Ho sold 17,500 shares of the firm’s stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $21.72, for a total transaction of $380,100.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,167 shares of company stock valued at $1,060,456. 21.30% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in Denali Therapeutics stock. Bank of New York Mellon Corp lifted its stake in shares of Denali Therapeutics Inc (NASDAQ:DNLI) by 17.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 61,196 shares of the company’s stock after purchasing an additional 8,882 shares during the period. Bank of New York Mellon Corp owned 0.06% of Denali Therapeutics worth $933,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 65.06% of the company’s stock.

Separately, Zacks Investment Research lowered shares of Denali Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, August 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $23.25.

COPYRIGHT VIOLATION NOTICE: This article was originally published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Further Reading: The risks of owning bonds

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply